While genetic alterations such as TP53, isocitrate dehydrogenase (IDH), cyclin dependent kinase inhibitor 2A (CDKN2A) mutations and chromosome 1p/19q codeletion are recognized contributors to glioma pathology, the importance of non-genetic factors in tumor progression and patient risk assessment is increasingly acknowledged [12]. The gene discussed is IDH1; the disease is central nervous system cancer.